Dr Erica Wilson – Senior Research Fellow
Dr Erica Wilson
Leeds Institute of Cancer and Pathology
Wellcome Trust Brenner Building
St James’s University Hospital
Beckett street, Leeds
tel: +44 (0) 113 343 8638
My current work focuses on immunology and immunotherapeutic strategies in Glioblastoma. I aim to understand how the immune system responds to immunotherapy in the brain, and develop a better understanding of this complex and immune tolerant environment. Many of my research questions centre around which of the resident and infiltrating immune cells respond to oncolytic viruses and how we might manipulate them for improved therapeutic effect within the unique microenvironment of the brain.
- Postdoctoral Research Fellow, Neuro-oncology LICAP, University of Leeds: 2014-
- The Brain Tumour Charity programme grant: Prof. Susan Short and Prof. Alan Melcher
- Postdoctoral Research Fellow, Oncology LICAP, University of Leeds: 2008-2014
- Yorkshire Cancer research project grants: Dr Graham Cook and Co-PI (see below)
- Senior Scientist, vVax Ltd, Leeds, UK: 2006-2008
- Postdoctoral Research Fellow, Terry Fox Laboratory, BCCRC, Vancouver, Canada: 2003-2006
- PhD Cancer immunotherapy, Department of Haematology, University of Cambridge: 1998-2003
- MRC PhD studentship
- BSc Biomedical Sciences (Immunology) 2:1, Kings College, London: 1995-1998
- Cancer Research UK internal development fund Co-PI Dr Milene Volpato: September 2012, £16,555; 1 year
Feasibility of reovirus and fish oil derivatives as therapeutic agents in murine models of colorectal cancer.
- Yorkshire Cancer Research project grant: April 2012, Co-PI £138,194; 2 yrs
Defining and exploiting TGF-β and type I interferon signaling in natural killer cells
Holmes TD, Wilson EB, Black EVI, Benest AV, , Vaz C, Tan B, Tanavde VM, Cook GP.
Licensed human natural killer cells aid dendritic maturation via TNSF14/LIGHT.
Proc Natl Acad Sci U S A. 2014, 111(52):E5688-96. doi: 10.1073/pnas.1411072112. Epub 2014 Dec 15.
El-Sherbiny YM1, Holmes TD, Wetherill LF, Black EV, Wilson EB, Phillips SL, Scott GB, Adair RA, Dave R, Scott KJ, Morgan RS, Coffey M, Toogood GJ, Melcher AA, Cook GP.
Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo.
Clin Exp Immunol. 2015, 180(1):98-107. doi: 10.1111/cei.12562.
Wilson EB, El-Jawhari J, Neilson A, Jennings V, Hall G, Melcher A, Meade JL, Cook GP.
Reversible TGF-β mediated inhibition of natural killer cells in the human tumour microenvironment.
PLoS One. 2011, 6(9):e22842. Epub 2011 Sep 6
Scott GB, Bowles PA, Wilson EB, Meade JL, Low BC, Davison A, Blair GE, Cook GP
Identification of the BCL2/adenovirus E1B-19K protein-interacting protein 2 (BNIP-2) as a granzyme B target during human natural killer cell-mediated killing.
Biochem J. 2010, Oct 11;431(3):423-31.
Meade JL, Wilson EB, Holmes TD, de Wynter EA, Brett P, Straszynski L, Ballard PA, Trapani JA, McDermott MF, Cook GP.
Proteolytic activation of the cytotoxic phenotype during human NK cell development.
J Immunol. 2009, Jul 15;183(2):803-13.
Wilson EB, Paranchoniak CA, Carpenito C, Mager DL, Takei F.
Expression of murine killer immunoglobulin-like receptor KIRL1 on CD1d-independent NK1.1(+) T cells.
Immunogenetics. 2007, 59 641-651.
Watkins NA, O’Connor M,N , Rankin A, Jennings N, Wilson EB, Harmer IJ, Davies L, Smethurst PA, Dudbridge F, Farndale RW and Ouwehand WH.
Definition of novel GP6 polymorphisms and major difference in haplotype frequencies between populations by a combination of in-depth exon resequencing and genotyping with tag single nucleotide polymorphisms.
J Thromb Haemost. 2006, Jun;4(6):1197-205.
Smethurst PA, Joutsi-Korhonen L, O’Connor MN, Wilson EB, Jennings NS, Garner SF, Zhang Y, Knight CG, Dafforn TR, Buckle A, Ijsseldijk MJW, Groot PG de, Watkins NA, Farndale RW and Ouwehand WH.
Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody.
Blood: 2004, 103, 903-911.
Kotecha MT, Afghan RK, Vasilikopoulou E, Wilson EB, Marsh P, Kast M, Davies DH and Caparros-Wanderley W.
Enhanced tumour growth after DNA vaccination against human papilloma virus E7 oncoprotein: evidence for tumour-induced immune deviation.
Vaccine: 2003, 21, 2506-15.